Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer

• Published in: Cancer research (Chicago, Ill.) Vol. 62; no. 14; pp. 4151 - 4156
• Main Authors: CHAN, Kelvin Y. K, OZCELIK, Hilmi, CHEUNG, Annie N. Y, NGAN, Hextan Y. S, KHOO, Ui-Soon
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 15-07-2002
• Subjects: Alleles; Base Sequence; Biological and medical sciences; DNA Methylation; Female; Female genital diseases; Gene Amplification; Gene Expression Regulation, Neoplastic - genetics; Genes, BRCA1; Genes, BRCA2; Gynecology. Andrology. Obstetrics; Humans; Medical sciences; Molecular Sequence Data; Ovarian Neoplasms - genetics; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger - biosynthesis; RNA, Messenger - genetics; Tumors; Human; Carcinoma; Sporadic; Nucleotide sequence; Pathogenesis; Transcription promoter; Gene overexpression; Malignant tumor; Gene expression; Female genital diseases; Ovarian diseases; Ovary; Gene silencing; GC rich sequence; DNA; Female; Methylation; Tumor suppressor gene
• ISSN: 0008-5472; 1538-7445

Hypermethylation of the BRCA1 promoter has previously been shown to cause reduced mRNA expression in both breast and ovarian cancers. Nothing is yet known of the expression pattern or methylation status of the promoter region of BRCA2 in sporadic ovarian cancer. Whereas our analysis of 30 sporadic ovarian carcinomas showed a statistically significant reduction of BRCA1 mRNA expression (P = 0.001), it also showed, in contrast, overexpression of BRCA2 mRNA (P = 0.002) in tumor compared with nontumor. Hypermethylation of the BRCA1 promoter highly correlated with decreased BRCA1 expression (P = 0.017). Methylated CpGs at the BRCA2 promoter were either absent or at very low levels in tumor DNA, whereas they were present at high levels in nontumor DNA. Such hypomethylation also correlated with elevated levels of BRCA2 mRNA (P = 0.043) and showed a statistically significant correlation with tumor stage (P = 0.037). This supports the role of methylation in BRCA2 contributing to the pathogenesis of sporadic ovarian cancer. Furthermore, 14 (58.2%) and 9 (56.3%) of all of the cases with aberrant BRCA mRNA expression and methylation patterns, respectively, demonstrated opposing mRNA expression and methylation patterns of the BRCA1 and BRCA2 genes within the same cases. Our findings suggest that both genes may be involved in the development of sporadic ovarian cancer.